• 1. Enabling chloride salts for thermal energy storage: implications of salt purity?
  J. Matthew Kurley,Phillip W. Halstenberg,Abbey McAlister,Stephen Raiman,Richard T. Mayes RSC Adv., 2019,9, 25602-25608
• 2. Fe/Fe3C@C nanoparticles encapsulated in N-doped graphene–CNTs framework as an efficient bifunctional oxygen electrocatalyst for robust rechargeable Zn–air batteries?
  Zhiyan Chen,Nan Wu,Yaobing Wang,Bing Wang,Yingde Wang J. Mater. Chem. A, 2018,6, 516-526
• 3. Fast-Track to Research Data Management in Experimental Material Science-Setting the Ground for Research Group Level Materials Digitalization.
  LarsBanko,AlfredLudwig
• 4. Evolved polymerases facilitate selection of fully 2′-OMe-modified aptamers?
  Zhixia Liu,Tingjian Chen,Floyd E. Romesberg Chem. Sci., 2017,8, 8179-8182
• 5. Fatty acid eutectic mixtures and derivatives from non-edible animal fat as phase change materials?
  Pau Gallart-Sirvent,Marc Martín,Gemma Villorbina,Mercè Balcells,Aran Solé,Luisa F. Cabeza,Ramon Canela-Garayoa RSC Adv., 2017,7, 24133-24139

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Oxazinanes Phenylmorpholines
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Oxazinanes Morpholines Phenylmorpholines

Methyl 2-amino-4-morpholinobenzoate (CAS No. 404010-84-0): A Comprehensive Overview

Methyl 2-amino-4-morpholinobenzoate (CAS No. 404010-84-0) is a specialized organic compound that has garnered significant attention in the field of pharmaceutical research and chemical synthesis. This compound, characterized by its unique structural features, exhibits promising properties that make it a valuable candidate for various applications, particularly in the development of novel therapeutic agents. The integration of morpholine and amino functional groups within its molecular framework imparts distinct chemical and biological characteristics, which are leveraged in contemporary research.

The molecular structure of Methyl 2-amino-4-morpholinobenzoate consists of a benzoic acid backbone substituted with an amino group at the 2-position and a morpholine ring at the 4-position. This arrangement not only contributes to its stability but also enhances its reactivity, making it a versatile intermediate in synthetic chemistry. The presence of the morpholine moiety is particularly noteworthy, as it is known for its ability to form stable complexes with various biomolecules, thereby influencing drug-target interactions.

In recent years, there has been a surge in research focused on developing small molecules with enhanced bioavailability and targeted action. Methyl 2-amino-4-morpholinobenzoate has emerged as a compound of interest due to its potential to modulate biological pathways associated with inflammation, neurodegeneration, and cancer. Its dual functionality allows for selective interactions with enzymes and receptors, which is crucial for designing drugs with minimal side effects.

One of the most compelling aspects of Methyl 2-amino-4-morpholinobenzoate is its role as a precursor in the synthesis of more complex pharmacophores. Researchers have utilized this compound to develop derivatives that exhibit improved pharmacokinetic profiles and enhanced therapeutic efficacy. For instance, studies have shown that modifications at the amino and morpholine positions can significantly alter the compound's solubility, metabolic stability, and binding affinity to biological targets.

The pharmacological potential of Methyl 2-amino-4-morpholinobenzoate has been explored in several preclinical studies. These investigations have highlighted its ability to inhibit key enzymes involved in inflammatory responses, such as cyclooxygenase (COX) and lipoxygenase (LOX). Additionally, preliminary data suggest that this compound may have neuroprotective properties, making it a promising candidate for treating neurodegenerative disorders like Alzheimer's and Parkinson's disease.

The synthesis of Methyl 2-amino-4-morpholinobenzoate involves multi-step organic reactions that require precise control over reaction conditions to ensure high yield and purity. Advanced synthetic methodologies, including palladium-catalyzed cross-coupling reactions and enzymatic transformations, have been employed to optimize the production process. These techniques not only improve efficiency but also minimize waste generation, aligning with the principles of green chemistry.

The analytical characterization of Methyl 2-amino-4-morpholinobenzoate has been conducted using state-of-the-art spectroscopic techniques such as nuclear magnetic resonance (NMR) spectroscopy, mass spectrometry (MS), and high-performance liquid chromatography (HPLC). These methods provide detailed insights into the compound's structure and purity, ensuring that it meets the stringent requirements for pharmaceutical applications.

In conclusion, Methyl 2-amino-4-morpholinobenzoate (CAS No. 404010-84-0) represents a significant advancement in the field of medicinal chemistry. Its unique structural attributes and promising biological activities position it as a valuable tool for drug discovery and development. As research continues to uncover new applications for this compound, it is expected to play an increasingly important role in addressing some of the most challenging medical conditions facing society today.

• 42106-48-9(2-(morpholin-4-yl)benzoic acid)
• 192817-79-1(2-Morpholin-4-Yl-Benzoic Acid Ethyl Ester)
• 23676-05-3(Methyl 4-morpholinobenzoate)
• 153437-52-6(2-amino-5-(morpholin-4-yl)benzoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)